Skip to content
AnalystLens

AbbVie Inc. 8-K Report, Corporate Update (Feb 19, 2025)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed February 19, 2025
Period End
February 18, 2025
Security
ABBV
In the record · 2016–202610-K1110-Q328-K163

ABBV filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 163 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’16Nov ’16
  2. Material agreement8-K · May ’20May ’20
  3. Leadership change8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed February 19, 2025. Cited figures are marked; the original filing is the authoritative source.

AbbVie Inc. (ABBV) announced a significant debt financing transaction via an 8-K filing on February 18, 2025.

The company has entered into an underwriting agreement to issue and sell approximately $3.98 billiona in aggregate principal amount of senior notes across various maturities in 2028, 2030, 2035, and 2055, with coupon rates ranging from 4.650% to 5.600%. These notes are being issued under AbbVie's existing universal shelf registration statement. The primary purpose of this debt issuance is to refinance upcoming maturities of existing senior notes, specifically addressing the 3.600% senior notes due May 2025 ($3.750 billion), 3.800% senior notes due March 2025 ($2.890 billion), and a portion of Allergan Funding SCS's 3.800% senior notes due March 2025 ($130.225 million).

This strategic move aims to manage AbbVie's debt profile and secure long-term funding. The net proceeds, after underwriting discounts, are expected to cover these repayment obligations, with any residual funds designated for general corporate purposes.

02—Key points

Key Highlights

  1. AbbVie is issuing $3.98 billion in new senior notes due 2028, 2030, 2035, and 2055.
  2. The new notes carry coupon rates ranging from 4.650% to 5.600%.
  3. Proceeds will be used to repay or redeem approximately $6.77 billion in existing senior notes maturing in March and May 2025.
  4. This is a proactive debt management strategy to address near-term maturities.
  5. The offering is registered under AbbVie's existing shelf registration statement filed on February 14, 2025.
  6. The closing of the sale is expected on February 26, 2025.
  7. A portion of the funds may also be used for general corporate purposes.

03—Questions

Frequently Asked Questions

  1. What is the purpose of this debt issuance?

    The primary purpose of this debt issuance is to refinance and repay upcoming maturities of AbbVie's existing senior notes, specifically those due in March and May 2025. This includes the 3.600% senior notes due May 14, 2025, and the 3.800% senior notes due March 15, 2025, as well as a portion of Allergan Funding SCS's 3.800% senior notes due March 15, 2025.

  2. How much money did AbbVie raise and at what cost?

    AbbVie raised approximately $3.98 billion in aggregate principal amount through the issuance of four series of senior notes. The notes carry fixed interest rates between 4.650% (for the 2028 notes) and 5.600% (for the 2055 notes).

  3. What are the terms of the new senior notes being issued?

    AbbVie is issuing senior notes with the following principal amounts and interest rates: $1.25 billion of 4.650% senior notes due 2028, $1.0 billion of 4.875% senior notes due 2030, $1.0 billion of 5.200% senior notes due 2035, and $750 million of 5.600% senior notes due 2055.

  4. Does this issuance affect AbbVie's credit rating or financial leverage?

    While the 8-K filing itself does not comment on credit ratings, a debt issuance of this magnitude to refinance existing debt is a common capital markets activity. Investors should monitor AbbVie's credit ratings from agencies like Moody's and S&P, and its subsequent financial reports for any commentary on leverage ratios and the impact of these new debt obligations on its overall financial structure.

04—Continue

← View all 8-K filings